Form 4: Arcutis CEO Watanabe Reports Equity Transactions

Arcutis Biotherapeutics CEO Todd Watanabe reported the acquisition of new equity awards and sales of shares to cover tax obligations.

Summary

• Todd Watanabe, President and CEO of Arcutis Biotherapeutics, Inc. (ARQT), reported transactions involving the company's common stock and derivative securities.
• Acquired 102,000 Restricted Stock Units (RSUs) on February 27, 2026, which will vest 25% annually starting March 1, 2027.
• Acquired 266,000 stock options with an exercise price of $26.97 on February 27, 2026, vesting 1/48th monthly from March 1, 2026, over four years.
• Sold 36,281 shares of common stock at a weighted average price of $25.1606 on March 2, 2026, to cover tax withholding obligations related to RSU vesting.
• Sold an additional 1,068 shares of common stock at a weighted average price of $25.9139 on March 2, 2026, also for tax withholding.
• Following these transactions, Watanabe directly beneficially owns 785,957 shares of common stock and indirectly owns 25,410 shares via The John Franklin Watanabe Trust, 25,410 shares via The Anderson Prest Watanabe Irrevocable Trust, 57,358 shares via Watanabe Ventures, LLC, and 124,956 shares via The Watanabe 2016 Irrevocable Trust.
• Beneficially owns 266,000 stock options directly.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive event, reflecting routine executive compensation and a continued alignment of the CEO's interests with the company's long-term performance through new equity awards, despite the expected tax-related sales.

Positives

• The reporting person, Todd Watanabe, received a significant grant of 102,000 Restricted Stock Units (RSUs) and 266,000 stock options, aligning his interests with long-term shareholder value.
• The acquisition of new equity awards demonstrates continued commitment and incentive for the CEO.

Negatives

• The sale of 37,349 shares of common stock (36,281 + 1,068) was executed to cover tax withholding obligations, which is a routine but non-discretionary reduction in direct holdings.

Future Outlook

The filing details future vesting schedules for RSUs and stock options, indicating a long-term incentive structure for the CEO, with vesting extending several years into the future.

Industry Context

StockSavvy.ai notes that equity compensation, including RSUs and stock options with multi-year vesting schedules, is a standard practice in the biotechnology industry to attract and retain executive talent and align management incentives with long-term company performance. The tax-related sales are also a common occurrence following the vesting of such awards.

Comparison to Industry Standards

• The grant of RSUs and stock options to a CEO is a common compensation practice, comparable to similar grants observed at other publicly traded biotechnology companies of similar market capitalization.
• The vesting schedules (25% annually for RSUs, 1/48th monthly for options over four years) are typical for executive equity awards, designed to promote long-term retention and performance.

Related Party Transactions

• Indirect beneficial ownership of common stock is held through The John Franklin Watanabe Trust, The Anderson Prest Watanabe Irrevocable Trust, Watanabe Ventures, LLC, and The Watanabe 2016 Irrevocable Trust, where the reporting person serves as trustee or COO, or whose children are beneficiaries. The reporting person disclaims beneficial ownership except to the extent of pecuniary interest.

Stakeholder Impact

• Shareholders: The new equity awards align the CEO's long-term incentives with shareholder value. The tax-related sales are routine and do not indicate a change in management's outlook.
• Employees: Standard equity compensation practices for executives can set a precedent for broader employee incentive programs.

Next Steps

• 25% of the acquired RSUs will vest annually on March 1st, beginning March 1, 2027.
• 1/48th of the acquired stock options will vest on each monthly anniversary from March 1, 2026, with full vesting on the fourth anniversary.

Key Dates

Keywords

Arcutis Biotherapeutics, ARQT, Todd Watanabe, Form 4, Insider Transaction, Restricted Stock Units, Stock Options, Equity Compensation, Biotechnology